Nasdaq:US$32.30 (+0.56) | HKEX:HK$49.55 (-1.35) | AIM:£4.69 (-0.02)
2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
13
HKEX
11
IN-HOUSE DISCOVERED
CLINICAL STAGE DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
1
NDA SUBMITTED IN THE US &
MAA SUBMITTED TO THE EMA
~40
CLINICAL TRIALS
AROUND THE GLOBE
1,400
DEDICATED SCIENTIFIC AND
COMMERCIAL PERSONNEL

OUR SCIENCE

Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.

R&D Philosophy Pipeline Products

Events, Circulars And Forms


Corporate Presentation for Investors 2021-09-21
Jefferies Asia Forum 2021-09-08
Chinese Society of Clinical Oncology 2021 Annual Meeting 2021-09-25 - 2021-09-29